For the quarter ending 2025-09-30, BRNS made $16,014K in revenue. -$14,566K in net income. Net profit margin of -90.96%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Total revenue-License | 0 | - | - | - |
| Total revenue | 0 | - | 14,969 | - |
| Research and development | 5,390 | 7,953 | 11,139 | 11,662 |
| General and administrative | 5,165 | 15,384 | 13,420 | 7,201 |
| Impairment of long-lived assets | 4,667 | - | - | - |
| Total operating expenses | 15,222 | 23,337 | 24,559 | 18,863 |
| Other operating income | 156 | 13 | 210 | 577 |
| Loss from operations | -15,066 | -23,324 | -9,380 | -18,286 |
| Interest income | 472 | 523 | 631 | 635 |
| Interest expense | 13 | 12 | 17 | 12 |
| Research and development incentives | 240 | 1,342 | 608 | 693 |
| Other income | -275 | 320 | 26 | 20 |
| Total other income, net | 424 | 2,173 | 1,248 | 1,336 |
| Loss before income tax | -14,642 | -21,151 | -8,132 | -16,950 |
| Tax benefit | -71 | -25 | -3 | -7 |
| Net loss | -14,571 | -21,126 | -8,129 | -16,943 |
| Net loss attributable to noncontrolling interest | -5 | -2 | -15 | -12 |
| Net loss attributable to barinthus biotherapeutics plc shareholders | -14,566 | -21,124 | -8,114 | -16,931 |
| Net loss per share attributable to ordinary shareholders, basic (in usd per share) | -0.36 | -0.52 | -0.21 | -0.43 |
| Net loss per share attributable to ordinary shareholders, diluted (in usd per share) | -0.36 | -0.52 | -0.21 | -0.43 |
| Weighted-average ordinary shares outstanding, basic (in shares) | 40,661,118 | 40,343,521 | 39,419,447 | 39,041,111 |
| Weighted-average ordinary shares outstanding, diluted (in shares) | 40,661,118 | 40,343,521 | 39,419,447 | 39,041,111 |
Barinthus Biotherapeutics plc. (BRNS)
Barinthus Biotherapeutics plc. (BRNS)